within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EE03_Binimetinib;

model Binimetinib
  extends Pharmacolibrary.Drugs.ATC.L.L01EE03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EE03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Binimetinib is an orally administered, small-molecule, selective inhibitor of MEK1 and MEK2 (mitogen-activated protein kinase kinases), used for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, typically in combination with other targeted therapies. It is currently approved for use by regulatory agencies such as the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in adult patients with advanced solid tumors, mainly metastatic melanoma, after oral administration of binimetinib as a single agent.</p><h4>References</h4><ol><li><p>Huynh, D, et al., &amp; Wollenberg, L (2025). The Absorption, Distribution, Metabolism, and Excretion of Binimetinib Following a Single Oral Dose of [. <i>Pharmacology research &amp; perspectives</i> 13(1) e70061–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.70061&quot;>10.1002/prp2.70061</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39887964/&quot;>https://pubmed.ncbi.nlm.nih.gov/39887964</a></p></li><li><p>Cao, L, et al., &amp; Chen, ZS (2023). Darovasertib, a novel treatment for metastatic uveal melanoma. <i>Frontiers in pharmacology</i> 14 1232787–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1232787&quot;>10.3389/fphar.2023.1232787</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37576814/&quot;>https://pubmed.ncbi.nlm.nih.gov/37576814</a></p></li><li><p>Bendell, JC, et al., &amp; Patnaik, A (2017). A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British journal of cancer</i> 116(5) 575–583. DOI:<a href=&quot;https://doi.org/10.1038/bjc.2017.10&quot;>10.1038/bjc.2017.10</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28152546/&quot;>https://pubmed.ncbi.nlm.nih.gov/28152546</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Binimetinib;
